Emmaus Life Sciences Inc (EMMA)
OTHER OTC:EMMA
Want to see EMMA full AI Analyst Report?
Top Page
Emmaus Life Sciences
(OTC:EMMA)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.01
▲(10.00% Upside)
Action:Reiterated
Date:06/02/26
The score is held down primarily by weak financial performance (ongoing losses, negative equity, and continued cash burn). Technicals are also soft with negative MACD and only neutral price positioning, while valuation remains unattractive due to losses and no dividend. A potentially positive supply-agreement catalyst provides some offset, but it is contingent and not yet de-risked.
Positive Factors
High gross margins
Sustained low-90%+ gross margins provide a durable profitability buffer versus peers. High product-level margins can support reinvestment in R&D or commercial access, improve leverage on incremental volume, and make supply/contract manufacturing economics attractive over a multi-month horizon.
Negative Factors
Persistent net losses and deep net margin
A ~-71% net margin and ongoing losses erode retained capital and limit the company’s ability to self-fund growth. Structurally negative profitability increases reliance on external financing, raises dilution risk, and constrains strategic optionality over several quarters unless substantial revenue or cost improvements continue.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained low-90%+ gross margins provide a durable profitability buffer versus peers. High product-level margins can support reinvestment in R&D or commercial access, improve leverage on incremental volume, and make supply/contract manufacturing economics attractive over a multi-month horizon.
Read all positive factors
Emmaus Life Sciences (EMMA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$708.90K
Dividend YieldN/A
Average Volume (3M)112.45K
Price to Earnings (P/E)―
Beta (1Y)54.64
Revenue Growth-27.33%
EPS Growth-83.64%
CountryUS
Employees34
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.13
Shares Outstanding70,188,260
10 Day Avg. Volume152,781
30 Day Avg. Volume112,453
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.01
Price to Sales (P/S)0.07
P/FCF Ratio-69.38
Enterprise Value/Market Cap44.56
Enterprise Value/Revenue2.63
Enterprise Value/Gross Profit2.81
Enterprise Value/Ebitda-596.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Emmaus Life Sciences Business Overview & Revenue Model
Company Description
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidat...
How the Company Makes Money
Emmaus generates revenue primarily from sales of its sickle cell disease therapy (its commercial L-glutamine-based product). Revenue is recognized from product sales to customers (e.g., distributors/wholesalers, pharmacies, hospitals, or other cha...
Emmaus Life Sciences Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
18
Very Negative
Cash Flow
20
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Jun 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 12.45M | 16.65M | 29.60M | 18.39M | 20.61M |
| Gross Profit | 11.60M | 15.45M | 28.25M | 15.80M | 17.30M |
| EBITDA | -310.00K | -910.00K | 3.62M | -5.50M | -12.76M |
| Net Income | -7.49M | -6.45M | -3.73M | -10.63M | -15.95M |
Balance Sheet | |||||
| Total Assets | 21.44M | 23.60M | 35.18M | 48.23M | 56.73M |
| Cash, Cash Equivalents and Short-Term Investments | 2.13M | 1.39M | 2.55M | 2.02M | 2.28M |
| Total Debt | 32.56M | 32.96M | 32.65M | 30.82M | 29.91M |
| Total Liabilities | 85.04M | 80.08M | 82.94M | 82.32M | 78.18M |
| Stockholders Equity | -63.61M | -56.48M | -47.76M | -34.09M | -21.45M |
Cash Flow | |||||
| Free Cash Flow | -12.00K | -2.30M | -1.52M | -5.10M | -1.33M |
| Operating Cash Flow | -11.00K | -2.29M | -1.50M | -5.07M | -1.25M |
| Investing Cash Flow | 2.17M | 2.50M | -432.00K | -2.39M | -6.38M |
| Financing Cash Flow | -1.43M | -1.35M | 2.48M | 7.23M | 7.41M |
Emmaus Life Sciences Technical Analysis
Negative
0.01
Price Trends
0.01
Negative
0.01
Negative
0.01
Negative
Market Momentum
>-0.01
Negative
44.03
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EMMA, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.03 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EMMA.
Emmaus Life Sciences Risk Analysis
Emmaus Life Sciences disclosed 32 risk factors in its most recent earnings report. Emmaus Life Sciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Emmaus Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
EMMA
Emmaus Life Sciences
0.01
>-0.01
-37.50%
SCNI
Scinai Immunotherapeutics
0.41
-2.14
-83.84%
ADTX
Aditxt
0.06
-37,588.25
-100.00%
DRMA
Dermata Therapeutics
1.18
-6.27
-84.16%
CERO
CERo Therapeutics Holdings
0.01
-9.08
-99.87%
CDT
CDT Equity
0.74
-537.26
-99.86%
Emmaus Life Sciences Corporate Events
Business Operations and Strategy
Emmaus Life Sciences Signs Exclusive Endari Supply Agreement
Positive
Mar 4, 2026
On March 2, 2026, Emmaus Life Sciences and South Korea–based NeoImmuneTech entered into an Exclusive Supply Agreement tied to their December 24, 2025 License and Exclusive Distribution Agreement. Under the new supply arrangement, once the li...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.